Boehringer Breathes Easy Over Spiriva Patent Expiry In US
The German group's pharma chief told Scrip that he does not expect to see any competition in the US in the short term to the soon-to-be off-patent COPD blockbuster, citing the complicated case of GSK's Advair for which there are still no FDA approved generics despite losing exclusivity a while ago.
You may also be interested in...
While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with COPD in NEJM, two clinicians in an accompanying editorial argue that the trial falls short of providing robust evidence for switching strategy.
Planned next generation of oral semaglutide 'is in the early research stage', Lars Fruergaard Jorgensen tells Scrip.
Companies are supporting new US-labeled indication for cardiovascular mortality risk reduction with a consumer education campaign, direct-to-consumer advertising and cardiologist detailing.